Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma DiveThe results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy.Immunology & InflammationRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) BioPharma Dive The results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy. Immunology & Inflammation Read full story Post navigation Previous: Beren pockets $300m to take Niemann-Pick disease therapy to marketNext: SonoThera bags $125M series B to advance safer gene therapies Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026